Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
08:37am, Monday, 03'rd Jun 2024
GSK shares plunged Monday after the Delaware State Court ruled that expert witnesses can present scientific evidence in the roughly 75,000 cases relating to the discontinued heartburn drug Zantac. The
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer.
GSK: Zantac litigation obscures the positives, says leading investment bank
04:17am, Monday, 03'rd Jun 2024
Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as it focused on the long-term potential of the stock. After hours on
GSK shares tumble 10% after Zantac ruling
03:23am, Monday, 03'rd Jun 2024
GSK shares dropped 10% after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition. GSK said it
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward
03:21am, Monday, 03'rd Jun 2024
Shares in British drugmaker GSK dropped more than 9% on Monday after a Delaware judge allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward.
GSK to appeal US judge's Zantac ruling
02:54am, Monday, 03'rd Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forw
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma.
GSK blood cancer drug nearly halves risk of death in late-stage trial
08:03am, Sunday, 02'nd Jun 2024
GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage s
Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 31'st May 2024
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK development pipeline underrated suggests Deutsche Bank
08:39am, Thursday, 30'th May 2024
GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the inno
AstraZeneca started at buy at Goldman, which rates GSK a neutral
06:34am, Thursday, 30'th May 2024
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
GSK plc: Long-Term Cash Cow
03:05am, Tuesday, 28'th May 2024
On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 mi
GSK found not guilty in Zantac trial
02:34am, Friday, 24'th May 2024
British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 23'rd May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
12:16pm, Wednesday, 22'nd May 2024
GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.
